- NEWS
The underdog coronavirus vaccines that the world will need if front runners stumble
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 585, 332-333 (2020)
doi: https://doi.org/10.1038/d41586-020-02583-z
References
Sun, W. et al. Preprint at bioRxiv https://doi.org/10.1101/2020.07.30.229120 (2020).
Case, J. B. et al. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.07.018 (2020).
Hassan, A. O. et al. Cell https://doi.org/10.1016/j.cell.2020.08.026 (2020).
Walls, A. C. et al. Preprint at bioRxiv https://doi.org/10.1101/2020.08.11.247395 (2020).
Coronavirus vaccines leap through safety trials — but which will work is anybody’s guess
What the immune response to the coronavirus says about the prospects for a vaccine
Latin American scientists join the coronavirus vaccine race: ‘No one’s coming to rescue us’
If a coronavirus vaccine arrives, can the world make enough?
Coronavirus vaccine trials have delivered their first results — but their promise is still unclear
Anti-vaccine movement could undermine efforts to end coronavirus pandemic, researchers warn
